文献速递药物不良反应与药物警戒抗栓抗凝管理

依替巴肽致迟发型重度血小板减少症一例

Delayed-onset eptifibatide-induced thrombocytopenia.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

本文报告一例62岁男性冠心病患者,在计划血运重建前接受依替巴肽(2 µg/kg/min)及肝素治疗后约5天,出现重度血小板减少,血小板从入院时249 × 10^3/µL骤降至低于1 × 10^3/µL。停用依替巴肽和肝素并换用阿加曲班后,血小板在2天内恢复至38 × 10^3/µL。依替巴肽血小板抗体检测示IgG介导反应阳性,Naranjo评分为4分,提示可能为依替巴肽所致不良反应。

要点

  • 依替巴肽所致血小板减少通常发生于用药24小时内,但本品可发生迟发型反应。
  • 使用依替巴肽期间应监测血小板计数,警惕迟发型重度血小板减少。
  • 怀疑依替巴肽相关血小板减少时应停药并考虑替代抗凝治疗。

核心结论

  • 这是首例已发表的、在依替巴肽启用超过24小时后发生的重度依替巴肽诱导血小板减少症病例报告,提示该药可发生迟发型反应。

研究设计与样本

  • 个案病例报告:一例62岁男性冠心病患者,有冠状动脉疾病史(包括过去12个月内经皮冠状动脉介入治疗)。

主要发现

  • 患者在计划心脏血运重建术前因显著血栓负荷启用依替巴肽2 µg/kg/min,并同时启用肝素抗凝。
  • 约5天后出现重度血小板减少,血小板从入院时249 × 10^3/µL骤降至低于1 × 10^3/µL。
  • 停用依替巴肽和肝素并换用阿加曲班后,血小板在接下来2天内恢复至38 × 10^3/µL。
  • 依替巴肽血小板抗体检测阳性,符合IgG介导反应,与依替巴肽诱导血小板减少症一致。
  • Naranjo量表评分为4分,提示可能为依替巴肽所致不良反应。

关键数值与推荐

  • 依替巴肽给药剂量为2 µg/kg/min。
  • 血小板计数从入院时249 × 10^3/µL降至低于1 × 10^3/µL。
  • 停药并换用阿加曲班后2天内血小板恢复至38 × 10^3/µL。
  • Naranjo评分为4分,提示可能的不良反应。

临床怎么用

  • 临床使用依替巴肽时不应仅局限于用药24小时内监测血小板,需警惕迟发型重度血小板减少。
  • 一旦怀疑依替巴肽相关血小板减少,应及时停药并评估替代抗凝方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present a unique case of delayed-onset, profound eptifibatide-induced thrombocytopenia that occurred 5 days after initiation of the drug. SUMMARY: Eptifibatide is a platelet glycoprotein IIb/IIIa receptor inhibitor with indications for use in patients with acute coronary syndromes. Eptifibatide-induced thrombocytopenia is uncommon but well studied and typically occurs within 24 hours of initiation of the drug. In the case described here, a 62-year-old male with a past history of coronary artery disease (including percutaneous coronary intervention within the past 12 months) was started on eptifibatide at a dosage of 2 µg/kg per minute for management of significant thrombus burden prior to a planned cardiac revascularization procedure; heparin for anticoagulation was also initiated. About 5 days after initiation of eptifibatide, the patient developed severe thrombocytopenia, with the platelet count dropping precipitously from 249 × 103/µL on admission to less than 1 × 103/µL. After eptifibatide and heparin therapy were discontinued and the patient was switched to argatroban, the platelet count recovered to 38 × 103/µL over the next 2 days. An eptifibatide platelet antibody assay was positive for IgG-mediated reactions consistent with eptifibatide-induced thrombocytopenia. Scoring of this case with the Naranjo scale yielded a score of 4, suggesting a possible adverse reaction to eptifibatide. CONCLUSION: This is the first published case report of profound eptifibatide-induced thrombocytopenia occurring more than 24 hours after eptifibatide initiation and serves to bring awareness that a delayed reaction can occur.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Huffman T, Gleaves E, Lenoir G, et al. Delayed-onset eptifibatide-induced thrombocytopenia. Am J Health Syst Pharm. 2024. PMID: 37884759. doi:10.1093/ajhp/zxad271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。